4:44 PM
 | 
Apr 26, 2019
 |  BC Extra  |  Company News

Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country.

"Everything we've seen happening over the last year or two in China goes in the right direction," Soriot said during the pharma's 1Q19 earnings call Friday.

Asked to respond to a news report that China has offered eight years of market exclusivity for biologics during U.S.-China trade talks, which falls shy of the 12-year market exclusivity under U.S. law, Soriot said the...

Read the full 440 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >